60
Views
18
CrossRef citations to date
0
Altmetric
Original Article

The Major Vault Protein (MVP), a New Multidrug Resistance Associated Protein, is Frequently Expressed in Multiple Myeloma

, , , , &
Pages 315-324 | Received 27 Feb 1998, Accepted 01 Oct 1998, Published online: 01 Jul 2009

References

  • Kyle R. Diagnosis and management of multiple myeloma and related disorders. Pr Hematol 1986; 14: 257
  • Durie B, Salmon S. The current status and future prospects of treatment of multiple myeloma. Clin Haematol 1982; 11: 181
  • Dalton W, Grogan T, Rybski J, Scheper R, Richter L, Kailey J, Broxtennan H, Pinedo H, Salmon S. Immunohistochemi-cal detection and quatitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 1989; 73: 747
  • Salmon S, Grogan T, Miller T, Scheper R, Dalton W. Prediction of doxorubicin resistance in vitro in myeloma. lymphoma, and breast cancer by p-glycoprotein staining. Journal of the National Cancer Institute 1989; 81: 696
  • Grogan T, Spier C, Salmon S, Matzner M, Rybski J, Wein-Stein R, Scheper R, Dalton W. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490
  • Salmon S, Dalton W, Grogan T, Plezia P, Lehnert M, Roe D, Miller T. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 778: 44
  • Sonneveld P, Dune B, Lokhorst H, Marie J-P, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K. Modulation of multi-drug-resistant multiple myeloma by cyclosporin. The Lancet 1992; 340: 255
  • Cole S, Bhardwaj G, Gerlach J, Mackie J, Grant C, Almquist K, Stewart A, Kurz E, Duncan A, Deeley R. Overexpression of a transporter gene in multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650
  • Flens M, Zaman G, Van Der Valk P, Izquierdo M, Schroeijers A, Scheffer G, Van Der Groep P, De Haas M, Meijer C, Scheper R. Tissue distribution of the multidrug resistance protein. American Journal of Pathology 1996; 148: 1237
  • Grant C, Valdimarsson G, Hipfner D, Almquist K, Cole S, Deeley R. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Research 1994; 54: 357
  • Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, Van Heijningen TH, Van Kalken CK, Slovak ML, De Vries EG, Van Der Valk P, Meijer CJ, Pinedo HM. Overexpression of a Mr 100,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Research 1993; 53: 1475
  • Izquierdo M, Scheffer G, Flens M, Giaccone G, Broxterman H, Meijer C, Van Der Valk P, Scheper R. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. American Journal of Pathology 1996; 148: 877
  • Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. Nature Medicine 1995; 1: 578
  • Schuurhuis G, Broxterman H, Cervantes A, Van Heijningen T, De Lange J, Baak J, Pinedo H, Lankelma J. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. Journal of the National Cancer Institute 1989; 81: 1887
  • List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996; 87: 2464
  • Izquierdo MA, Van Der Zee AG, Vermorken JB, Van Der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJ, De Vries EG, Scheper RJ. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. Journal of the National Cancer Institute 1995; 87: 1230
  • Den Boer ML, Pieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers GJL, Janka-Schauh G, Henze G, Creutzig U, Scheper RJ, Veerman AJP. Relationship between major vault protein/lung resistance protein, Multidrug resistance-associated protein, p-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092
  • Dalton W, Drurie B, Alberts D, Gerlach J, Cress A. Characterization of a new drug resistant human myeloma cell line that expresses p-glycoprotein. Cancer Research 1986; 46: 5125
  • Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resis-tant human multiple myeloma cell line. Cancer Research 1991; 51: 995
  • Futscher B, Abbaszadegen M, Domann F, Dalton W. Analysis of MRP mRNA in mitoxantrone-selected. multidrug resistant human tumor cells. Biochem Pharrnacol 1994; 47: 1601
  • Abbaszadegan M, Foley N, Gleason-Guzman M, Dalton W. Resistance to the chemosensitizer verapamil in a multi-drug resistant (MDR) human multiple myeloma cell line. International Journal of Cancer 1996; 66: 506
  • Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S. Optimization of immunocytochemical P-giycoprotein assessment in multidrug resistant plasma cell myeloma using three antibodies. Laboratory Investigation 1990; 63: 815
  • Grogan T, Rangel C, Rimsza L, . Kinetic-mode automated double labeled immunohistochemistry and in situ hybridization in diagnostic pathology. Advances in Pathology and Laboratory Medicine, R Weinstein, et al. Mosby, New York 1995; Vol. 8
  • Bhalla K, Hindenburg A, Taub R, Grant S. Isolation and characterization of an anthracycline-resistant human leuke-mic cell line. Cancer Research 1985; 45: 3657
  • Wyler B, Shao Y, Schneider E, Cianfriglia M, Scheper RJ, Frey BM, Gieseler F, Schmid L, Twentyman P, Lehnert M. Intermittent exposure to doxorubicin in vitro selects for mul-tifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. British Journal of Haematology 1996; 97: 65
  • Abbaszadegan M, Futscher B, Klimecki W, List A, Dalton W. Analysis of multidrug resistance-associated proteim (MRP) messenger RNA in normal and malignant hematopoi-etic cells. Cancer Research 1994; 54: 4676
  • Izquierdo M, Shoemaker R, Flens M, Scheffer G, Wu L, Prather T, Scheper R. Overlapping phenotypes of multidrug resistance among panels of human cancer cell Iines. International Journal of Cancer 1996; 65: 230
  • Wu L, Smythe A, Stinson S, et al. Multidrug resistant pheno-type of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Research 1992; 52: 3029
  • Izquierdo M, Scheffer G, Flens M, Shoemaker R, Rome L, Scheper R. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cyto-technology 1996; 19: 191
  • Izquierdo M, Neefjes J, Mathari A, Flens M, Scheffer G, Scheper R. Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. British Journal of Cancer 1961; 74: 1996
  • Goasguen J, Lamy T, Bergeron C, Ly Sunaram B, Mordelet E, Gone G, Dossot J, Le Gall E, Grosbois B, Le Prise P, Fauchet R. Multifactorial drug-resistance phenomenon in acute leukemias: impact of P170-MDR1, LRP56 protein, glutathione-transferases and metallothionein systems on clinical outcome. Leukemia and Lymphoma 1996; 23: 567
  • Danks M, Schmidt C, Cirtain M, Suttle D, Beck W. Altered catalytic activity of an DNA cleavage by DNA topoisomerase Il from human leukemic cells seiected for resistance to VM-26. Biochemistry 1988; 27: 8861
  • Raaijmakers HGP, IzquierdÖ MA, Lokhorst HM, De Leeuw C, Belien JAM, Bloem AC, Dekker AW, Scheper RJ, Sonn-Eveld P. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91: 1029
  • San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, Borrego D, Carnero M, Casanova F, Jimenez R, Portero JA, Orfao A. A new staging system for multiple myeloma based on the number of S-phase. plasma cells Blood 1995; 85: 448

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.